NONOF
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 10.93 | $96.8B | $12.0B |
| 2025 Q4 | 6.04 | $79.0B | -$10.8B |
| 2025 Q3 | 4.50 | $75.0B | $32.5B |
| 2025 Q2 | 5.96 | $76.9B | $24.5B |
| 2025 Q1 | 6.54 | $78.1B | $10.0B |
| 2024 Q4 | 6.34 | $85.7B | -$4.3B |
| 2024 Q3 | 6.13 | $71.3B | $31.7B |
| 2024 Q2 | 4.50 | $68.1B | $37.3B |